|Articles|September 1, 2004
COX-2 inhibitors have potential for treating orbital disease
All patients demonstrated marked improvement of the redness, swelling, and inflammationassociated with thyroid orbitopathy.
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
FDA grants IDE approval to EyeYon Medical for its US clinical study of EndoArt
2
First patient treated in ViaLase’s IDE trial
3
Ocular Therapeutix accelerates NDA submission plans for AXPAXLI for wet AMD
4
Formosa Pharmaceuticals and Rxilient sign licensing and commercialization agreement for APP13007
5











































.png)


